Search results for: Multi-Indication Medicines
Filter search results
Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
31 March 2015
…Institute for Health and Care Excellence (NICE). These activities are impeded if medicine use cannot be ascribed to indication. For example, multi-indication medicines were left out altogether from reports by…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…be inconsistent and distortionary for it to influence the multi-indication medicine policy context. This would put patient populations for whom treatment advances arise more commonly from multi-indication products – such…
Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
1 March 2015
…always expanding, one important limitation is the difficulty in assessing medicine use according to what that medicine has been used for, where the medicine has multiple indications. This impedes our…
A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
1 September 2021
Medicines for rare and ultra-rare conditions face distinct economic and ethical challenges compared to medicines for more common conditions. These challenges are implicitly acknowledged by the National Institute of Health…
Payment Models for Multi-Indication Therapies
1 November 2021
For the growing number of multi-indication medicines, access may be delayed or even denied due to challenges in linking payment with a medicine’s value across those indications. We assembled a…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
…OHE Briefing on the topic of multi-indication pricing. The briefing contains a summary of a workshop organised and facilitated by OHE and MME Europe. Multi-indication pricing (MIP) involves setting a…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
1 October 2015
…medicines are to reflect their value, then multi-indication medicines should have different prices across major indication, reflecting different values. Multi-indication pricing (MIP) involves setting a different price for each major…
Rare Disease Day 2024: Why Do We Care About Rare?
29 February 2024
…in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases – OHE. Office of Health Economics. Published January 9, 2021. Accessed February 27, 2024. https://www.ohe.org/publications/case-study-analysis-challenges-nice-evaluation-multi-indication-medicines-rare-and/ Cole A, Cubi-Molla…
Collaborating on Payment Models to Unlock the Potential of Multi-Indication Therapies.
22 June 2022, 2:00pm
…as monotherapy or in combination with other therapies as part of treatment regimens. For the growing number of these multi-indication medicines access may be delayed or even denied due to…